| Assessment Status | Assessment process complete |
| HTA ID | 20020 |
| Drug | Hydroxycarbamide solution |
| Brand | Xromi® |
| Indication | For the prevention of vaso-occlusive complications of sickle cell disease in patients over two years of age. |
| Assessment Process | |
| Rapid review commissioned | 20/04/2020 |
| Rapid review completed | 14/05/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that hydroxycarbamide (Xromi®) not be considered for reimbursement at the submitted price.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement; August 2020.
